Modality
Nanobody
MOA
SOS1i
Target
SMN2
Pathway
Incretin
IPF
Development Pipeline
Preclinical
~Feb 2023
→ ~May 2024
Phase 1
Aug 2024
→ Jun 2031
Phase 1Current
NCT03965653
1,794 pts·IPF
2025-03→2031-06·Active
NCT04439581
1,425 pts·IPF
2024-08→2028-07·Active
3,219 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-01-182mo agoConference· IPF
2028-07-192.3y awayPh2 Data· IPF
2031-06-055.2y awayPh2 Data· IPF
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P1/2
Active
P1/2
Active
Catalysts
Conference
2026-01-18 · 2mo ago
IPF
Ph2 Data
2028-07-19 · 2.3y away
IPF
Ph2 Data
2031-06-05 · 5.2y away
IPF
Active|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03965653 | Phase 1/2 | IPF | Active | 1794 | PANSS |
| NCT04439581 | Phase 1/2 | IPF | Active | 1425 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| REG-647 | Regeneron | Preclinical | SMN2 |